Bristol Myers Squibb (NYSE: BMY) is a global pharmaceutical company that discovers, develops, and delivers innovative medicines for patients. The company has a significant presence in key therapeutic areas, including oncology and cardiovascular disease. It competes with other major drugmakers like AstraZeneca (NASDAQ: AZN), with which it is reportedly in preliminary merger discussions.
On August 4, 2026, analyst firm RBC Capital maintained its "Sector Perform" rating on Bristol Myers Squibb. This type of rating is considered a "hold," suggesting that investors should maintain their current position in the stock. This neutral stance comes as the company's stock price was recorded at $65.47.
The rating follows media reports of a potential merger with AstraZeneca that could value the combined company near $400 billion. However, the deal faces skepticism due to the major regulatory hurdles it would likely encounter. Both companies hold dominant market shares in oncology, which could trigger antitrust reviews from regulators.
This uncertainty is shared by some analysts, as highlighted by Proactive Investors. Investment bank Jefferies describes the reported talks as "more than a head scratcher," questioning why AstraZeneca would use its equity to buy a company with a low earnings multiple. An earnings multiple helps investors gauge a company's value.
At the time of the rating, Bristol Myers Squibb shares were priced at $65.47, trading near the stock's 52-week high of $68.10. The company has a market capitalization of approximately $133.74 billion. Market capitalization is the total value of all a company's shares of stock.
